The decision came a few months ahead of Kite's possible approval for a highly personalized cancer treatments called CAR T-cell therapy. It's a form of cancer immunotherapy — or a therapy that harnesses the body's immune system to take on cancer cells.and more »
Renewed optimism in AstraZeneca's cancer treatment pipeline helped push the drugmaker to its biggest gain in four months on Thursday. AstraZeneca jumped 4.3 per cent to £47.74 after Bristol-Myers Squibb said a combination late-stage trial of its ...
No comments:
Post a Comment